Why Arvinas Jumped 10% Today

why arvinas jumped 10 today

Sumary of Why Arvinas Jumped 10% Today:

  • The two companies will co-develop and then co-market Arvinas’ ARV-471, currently in trials as a treatment for certain forms of breast cancer.
  • In addition to a $350 million equity investment in the $4 billion organization, Pfizer is also awarding Arvinas with an upfront payment of $650 million in exchange for shared rights to assist in the development and eventual marketing of ARV-471. Image source: Getty Images.
  • The drug in question is currently in phase 2 trials as a therapy for estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancers.
  • But Pfizer’s upfront payment and purchase of Arvinas — in addition to $1.4 billion worth of additional milestone awards — suggests the evidence of efficacy thus far is better than average.
  • Better still, given that the poorly served $20 billion breast cancer market could be worth twice as much in just a matter of years, at the very least Pfizer’s interest makes Arvinas a compelling prospect.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.